Life Sciences: Pharma Regulatory Submission Review with Claude Code: Build vs Buy Decision
A production playbook for pharma regulatory submission review in life sciences operations using Claude Code: build vs buy decision, run-scoped inputs, logs, typed results, and artifacts.
Audience: Life sciences regulatory teams
The problem
Life sciences regulatory teams need pharma regulatory submission review to run repeatedly against submission packets, study reports, labeling docs, and regulator comments. In life sciences operations, the pain is not one good answer; it is repeatability, auditability, exception handling, and evidence that survives handoff.
Implementation path
Compare the work required to operate pharma regulatory submission review: sandbox lifecycle, provider credentials, input injection, logs, artifact delivery, retries, and result validation.
Tradeoffs and failure modes
Building gives total control; buying the runtime compresses the path to a customer-facing workflow. For pharma regulatory submission review, the practical test is whether a second run can be debugged, retried, and consumed by a product without reading the raw agent transcript.
Decision table
Build internally if you need bespoke infrastructure primitives.
Use Argo if you need pharma regulatory submission review as a product workflow: inputs, Claude Code, logs, result JSON, and artifacts.
Use both if a specialized sandbox must sit behind a stable run contract.
Run this on Argo